Human immunodeficiency virus-infected people discontinuing therapy experience a rebound in the virus level (hereafter, "rebound virus") from a persistent reservoir. We examined 10 samples from patients in AIDS Clinical Trials Group study A5068 with rebound virus, using single-genome amplification and Primer ID deep sequencing, to assess env genetic diversity of the virus population. Most rebound-virus populations showed significant diversity. All env examined required high levels of CD4 for entry, consistent with selection of replication in CD4 + T cells. These results indicate that most people discontinuing therapy release a diverse population of virus and that this released virus has entry features of virus selected for replication in CD4 + T cells, rather than in myeloid cells.
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Successful antiretroviral therapy (ART) reduces the human immunodeficiency virus type 1 (HIV-1) load in the blood to stable low levels; however, ART does not eliminate virus. Most people discontinuing therapy experience a rebound in the virus level (hereafter, "rebound virus") from a persistent reservoir [1] [2] [3] [4] . The variable timing of rebound, where the virus is coming from, and the complexity of the rebound virus population are poorly understood.
One potential source of virus is latently infected resting CD4 + T cells. There is also a continual production of virus at low levels despite ART, and other cell types could be the source of rebound virus. In a largely quiescent reservoir, rebound virus could be clonal, as the result of virus from a single cell leaving a latent state. However, the number and complexity of rebound virus within a person has recently been predicted to be much higher than predicted on the basis of a largely quiescent reservoir [4] .
To this end, we used peripheral blood samples from patients in AIDS Clinical Trials Group study A5068 [5] to investigate the diversity and entry phenotype of rebound virus. Subjects in A5068 discontinued ART as part of an analytic treatment interruption (ATI) and had virologic rebound detectable in the blood 2-4 weeks, on average, after discontinuation of therapy.
To study the complexity of rebound virus, we assessed the genetic diversity of viral env and also examined viral entry phenotype. Phylogenetic analysis showed a high degree of diversity in the rebound virus population. In addition, all Env examined required high levels of CD4 for efficient entry, consistent with prior selection for replication in CD4 + T cells. Our analysis suggests that a viral population replicating in myeloid cells is not a significant source of rebound virus in blood early after the discontinuation of ART.
METHODS
A detailed description of the study methods is available in the Supplementary Materials. The parent trial is registered at Clin-icalTrials.gov (registration NCT00011011).
Study Population
All samples were collected under institutional review boardapproved protocols, and all subjects provided written informed consent. AIDS Clinical Trials Group study A5068 examined whether structured treatment interruptions and/or vaccination with an ALVAC-HIV vector was associated with control of viral replication during a subsequent ATI, compared with no vaccination or structured interruption control (arm A). The study showed a modest effect in reduced peak and set point viral load of rebound virus in the arms that included the structured treatment interruptions [5] . Subjects with the ATI only (arm A) had a median CD4 + T-cell count of 779 copies/mL and viral RNA levels of <50 copies per mL at entry while still receiving therapy. For our study, we used blood plasma samples from 10 of these subjects early after the initiation of the ATI, when viral load was ≥1000 copies/mL. For one subject, a pretherapy sample was also available.
Virus Characterization
Sequences of virion RNA were examined using single-genome amplification (SGA) [6] of full-length env and deep sequencing with Primer ID [7] of the V1-V3 region of env. Phylogenetic analysis of full-length env was used to select a representative sampling of amplicons for cloning to assess viral entry phenotype. env cloned in an expression vector was used in cotransfection with the pNL4-3.LucR-E reporter backbone plasmid into 293 T cells to generate an Env-pseudotyped luciferase reporter virus as described previously [8] [9] [10] . By comparing the ability of the pseudotyped virus to infect Affinofile cells expressing high versus low levels of surface CD4, we are able to consistently assess the viral CD4 entry phenotype as largely restricted to CD4 + T cells when high levels of CD4 are required for entry (T-cell tropic), compared with tropism favoring cells with a low density of CD4, such as macrophages (macrophage tropic) [8] . Sensitivity to soluble CD4 (sCD4) was used to confirm the CD4 entry phenotype. Additionally, coreceptor use was analyzed using Maraviroc inhibition of CCR5.
RESULTS
We analyzed 11 plasma samples from 10 subjects (subject 43 656 had a pretherapy [R0] and rebound [R1] sample available; Figure 1A ). We used plasma from the first available time point at which the viral load was >1000 copies/mL, to focus on early rebound virus, with most samples yielding a viral load of <10 000 copies/mL ( Figure 1B ). Eight of ten subjects had nadir CD4 + T-cell counts before therapy of 201-500 cells/mL, while 1 (sample R10) was <201 cells/mL.
To determine the viral sequence diversity of the rebound samples, we performed deep-sequencing analysis with Primer ID to sequence the V1-V3 region of env [7] ( Figure 1D ), in addition to doing SGA of full-length env [6] . Deep-sequencing results were achieved for 8 of 10 rebound samples and the pretherapy sample (however, the rebound sample, R1, from the patient from whom the pretherapy sample was obtained did not yield deep-sequencing results). We estimated the minimum number of rebound viruses as distinct sequence lineages in the phylogenetic tree analysis and highlighter plots (Figures 1D and 2A and Supplementary Figures 1 and 2 ). We used both distinct lineages and complex clusters of linked sequence differences in forming this estimate while trying to avoid interpreting complexity that could have been the result of postrebound recombination. We consider these values as minimum estimates of rebound virus complexity since the viruses considered as potential recombinants could have preexisted in the reservoir and been independently reactivated. Analysis of the minimum number of lineages versus the time (in weeks) to rebound demonstrated no obvious correlation between the time to rebound and the complexity of the rebound virus population ( Figure 1C ). For virus that rebounded in the first few weeks, we estimated 1-5 distinct lineages by deep sequencing, with a mean of 3.1 lineages, for these early rebound viruses. R2 took the longest to rebound (10 weeks) and showed a relatively low diversity, with only 2 lineages. SGA of full-length env showed 1-4 distinct lineages, with a mean of 3.1 lineages, similar to the results obtained with deep sequencing ( Figure 1C ). The mean intrapatient diversity was also determined by pair-wise analysis using full-length env and was found to be 0.2%-3.1%. Additional analyses of 10 subjects with early phase infection (Supplementary Table 2 ) [11] and 7 with chronic infection who were not receiving therapy (unpublished data; Supplementary Table 3 ) were also done, revealing mean intrapatient diversity of 0.16%-1.2% ( Supplementary Figure 3 ) and 1.1%-4.1%, respectively. These numbers suggest that rebound virus is more similar to virus in chronically infected subjects, in whom multiple viral lineages form a genetically complex population.
We subsequently cloned 51 individual env genes (average, 4 amplicons/subject) from the major lineages in each participant to determine the entry phenotype of rebound virus, using the Affinofile cell line (Figure 2A and Supplementary Figure 2 ). The pretherapy sample (R0) was also included; no clones were obtained for sample R5. Affinofile cells allow controlled expression of CD4 and are currently the most consistent method to assess CD4-dependent entry phenotype [8] . Entry phenotype was evaluated on the basis of the ability of viruses pseudotyped with Env from rebound virus to infect Affinofile cells expressing either high or low levels of CD4. The phenotype was confirmed by sensitivity to inhibition by sCD4 at a concentration of 5.0 µg/mL when infecting TZM-bl cells [12] ; this concentration neutralizes macrophage-tropic viruses but not R5 T-cell-tropic viruses. No Env showed any (<2% infection) ability to infect cells expressing low levels of CD4 as compared to their infectivity on cells expressing high levels of CD4 ( Figure 2B) , and they were also resistant to inhibition by sCD4 ( Figure 2D ). In addition, all pseudotyped viruses were inhibited by the CCR5 antagonist maraviroc, and therefore all isolated Env used CCR5 as the coreceptor. Taken together, all Env tested from rebound virus from all subjects had a phenotype consistent with that of R5 T-cell-tropic virus.
DISCUSSION
In this report, we describe 2 key features of the initial virus that rebounds from the latent or low-level viremia reservoir after therapy discontinuation. These features are relevant to developing strategies of HIV-1 eradication because they are features of the first virus that must be targeted. We asked what the entry phenotype was of this virus, to determine what cell type it had been predominantly replicating in at the time therapy was initiated and/or it entered the latent reservoir. In addition, we examined the complexity of the rebound population as a measure of the minimum number of viruses that rebound from the reservoir and become detected in the blood. The genetic diversity of the viral reservoir and rebound virus has been debated but it is perceived to be low and to be primarily clonal or multiclonal [13, 14] . Our results are consistent with the observation of Rothenberger et al [4] , who proposed a multifocal model of virus reactivation. Counting major lineages with both deep sequencing and SGA, we observed a mean of 3.1 distinct lineages, which suggests a minimum of 3 viruses rebounding within a short period after treatment interruption. While this is significantly less than the 5-25 rebound/founder viruses suggested by Rothenberger et al [4] , when we reanalyzed the sequence data from that study for the 3 subjects with SGA of virion RNA by using the same criteria as used in this report, we found that the mean number of distinct lineages was 3.3, similar to what we observed (Supplementary Methods). However, since we did not count potential recombinants in our analysis, this is a minimum estimate.
The number of rebound viruses could be affected by factors that affect viral reservoir size, such as ART duration and time to ART initiation after infection, but such data are not available for these subjects. Reservoir size, as measured by cell-associated viral RNA and DNA, has been shown to be correlated with set point after therapy discontinuation [15] . Sample R2 had one of the lowest sequence diversities (0.59%) and took the longest to have a measurable rebound virus population, but we only analyzed one subject for whom >4 weeks passed before rebound was detected.
The use of viral outgrowth assays from subjects receiving therapy after isolation of resting CD4 + T cells and reactivation in culture has established this cell type as a reservoir for HIV-1 latency [1] [2] [3] . We sought to evaluate the rebound virus population by using entry phenotype. Distinct lineages of HIV-1 can evolve the ability to use low levels of CD4 for entry, but these have been found primarily in the cerebral spinal fluid; presumably, this localized evolution is due to selective pressure to enhance replication in cells such as macrophages, which express low levels of CD4. Here we assessed the CD4 entry phenotype in conjunction with sCD4 sensitivity (a feature of low CD4using Env) to determine that rebound viruses needed high levels of CD4 for efficient entry ( Figure 2B ). Sensitivity to inhibition by maraviroc of all Env showed that all of the viruses used CCR5 ( Figure 2C ), making these viruses R5 T-cell tropic. On the basis of this phenotypic characterization, we can conclude that rebound virus was adapted to replicating in CD4 + T cells at the time the reservoir was formed. These results do not define the cell type that harbored the latent virus before rebound (T cells or macrophages), but these results exclude the possibility that rebound virus was replicating extensively in a myeloid cell lineage before latency, since this would have selected for the ability to use low levels of CD4 for entry. It should be noted, however, that viral rebound in isolated compartments of the body, such as the brain, or viruses released later from smaller reservoirs could have phenotypes that are distinct from that of the initial rebound virus that predominates in the blood.
In summary, we have shown that the early rebound virus is more diverse than previously thought. Additionally, we were able to show that all virus isolates from the plasma used CCR5 and required high levels of CD4 for entry and therefore were R5 T-cell tropic. This excludes a population of virus replicating in myeloid cells as a significant contributor to the viral reservoir that repopulates blood early after therapy discontinuation.
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